H0648g, BCIRG 007, and other studies showed that trastuzumab combined with chemotherapy significantly prolonged the survival time of BC patients with HER2 overexpression (IHC 3 + or IHC 2 + with ISH positivity) [2, 3]. Here, ERBB2 is linked to breast cancer.